| Literature DB >> 28844694 |
Gaylor Boulay1, Gabriel J Sandoval2, Nicolo Riggi3, Sowmya Iyer4, Rémi Buisson5, Beverly Naigles6, Mary E Awad6, Shruthi Rengarajan6, Angela Volorio7, Matthew J McBride2, Liliane C Broye3, Lee Zou5, Ivan Stamenkovic3, Cigall Kadoch8, Miguel N Rivera9.
Abstract
Alterations in transcriptional regulators can orchestrate oncogenic gene expression programs in cancer. Here, we show that the BRG1/BRM-associated factor (BAF) chromatin remodeling complex, which is mutated in over 20% of human tumors, interacts with EWSR1, a member of a family of proteins with prion-like domains (PrLD) that are frequent partners in oncogenic fusions with transcription factors. In Ewing sarcoma, we find that the BAF complex is recruited by the EWS-FLI1 fusion protein to tumor-specific enhancers and contributes to target gene activation. This process is a neomorphic property of EWS-FLI1 compared to wild-type FLI1 and depends on tyrosine residues that are necessary for phase transitions of the EWSR1 prion-like domain. Furthermore, fusion of short fragments of EWSR1 to FLI1 is sufficient to recapitulate BAF complex retargeting and EWS-FLI1 activities. Our studies thus demonstrate that the physical properties of prion-like domains can retarget critical chromatin regulatory complexes to establish and maintain oncogenic gene expression programs.Entities:
Keywords: EWS-FLI1; Ewing sarcoma; enhancers; epigenetics; intrinsically disordered proteins; mSWI/SNF (BAF) complexes; microsatellite repeats; phase transition; pioneer factor; prion-like domains
Mesh:
Substances:
Year: 2017 PMID: 28844694 PMCID: PMC6791823 DOI: 10.1016/j.cell.2017.07.036
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582